Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
Wave Life Sciences Ltd. - Ordinary Shares (WVE)
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.wavelifesciences.com/news-releases?page=1%2c0%2c0%2c0
Company Research
Source: GlobeNewswire
RestorAATion-2 clinical trial of WVE-006 in AATD patients underway; expected proof-of-mechanism data in patients with AATD remains on track for 2024 INHBE program for obesity expected clinical trial initiation in 1Q 2025; preclinical data demonstrate weight loss similar to semaglutide, fat loss with no loss of muscle mass, and curtailed rebound weight gain upon cessation of semaglutide, with potential for dosing 1 – 2 times per year Continued momentum in GSK collaboration; advancing first two GSK collaboration programs following successful target validation; both programs utilize Wave’s GalNAc-siRNA format and discovery collaboration continues to span all Wave modalities, including RNA editing Clinical data on track for first-in-class, allele-selective HD program (expected 2Q 2024) and potentially registrational FORWARD-53 trial in DMD (expected 3Q 2024) Cash and cash equivalents of $181 million as of March 31, 2024; with an additional $12 m
Show less
Read more
Impact Snapshot
Event Time:
WVE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WVE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WVE alerts
High impacting Wave Life Sciences Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
WVE
News
- Wave Life Sciences Ltd. (NASDAQ: WVE) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $11.00 price target on the stock.MarketBeat
- Wave Life Sciences Ltd. (NASDAQ:WVE) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates [Yahoo! Finance]Yahoo! Finance
- Wave Life Sciences Ltd. (NASDAQ: WVE) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Wave Life Sciences Ltd. (NASDAQ:WVE) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Wave Life Sciences First Quarter 2024 Earnings: US$0.24 loss per share (vs US$0.27 loss in 1Q 2023) [Yahoo! Finance]Yahoo! Finance
WVE
Earnings
- 5/9/24 - Miss
WVE
Sec Filings
- 5/10/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 4/29/24 - Form 10-K/A
- WVE's page on the SEC website